APAC Ovarian Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Description

List of Tables

The Asia-Pacific ovarian cancer diagnostics market is projected to register a substantial CAGR of 6.3% from 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

Asia-Pacific Ovarian Cancer Diagnostics Market- By Product Type (Instruments, Kits and Reagents), Procedure Type (Biopsy Test, Medical Imaging Test, Blood Markers Testing, Genetic Testing), Cancer Type (Germ Cell, Epithelial Tumor, Stromal Cell Tumor), End User (Cancer Diagnostic Centers, Hospital Laboratories, Research Institutes, Others), Country (China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of Asia-Pacific ovarian cancer diagnostics market are:

Growing ovarian cancer awareness

Improved diagnostic processes and techniques

Increase in number of new cases every year

Improved imaging techniques

Market Players:

The major companies which are dealing in the Asia-Pacific ovarian cancer diagnostics market are listed below:

F. Hoffmann-la roche ltd

Tosoh india pvt. Ltd.

Luminex corporation

Quest diagnostics incorporated

Thermo fisher scientific Inc.

Ngenebio

Abbott

Siemens healthcare private limited

Myriad genetics Inc.

Bio-rad laboratories, Inc.

R&d systems, Inc.

Inex innovate private limited

Abcam plc.

Monobind Inc.

Fujirebio

Mp biomedicals

Biovision Inc.

Boster biological technology

Biogenix Inc. Pvt. Ltd.

Genway biotech

Lifespan biosciences, Inc

1 INTRODUCTION 21

1.1 OBJECTIVES OF THE STUDY 21
1.2 MARKET DEFINITION 21
1.3 OVERVIEW OF ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET 21
1.4 LIMITATIONS 22
1.5 MARKETS COVERED 23

2 MARKET SEGMENTATION 25

2.1 MARKETS COVERED 25
2.2 GEOGRAPHICAL SCOPE 26
2.3 YEARS CONSIDERED FOR THE STUDY 27
2.4 CURRENCY AND PRICING 27
2.5 DBMR TRIPOD DATA VALIDATION MODEL 28
2.6 MULTIVARIATE MODELLING 31
2.7 PRODUCT TYPE LIFELINE CURVE 31
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 32
2.9 DBMR MARKET POSITION GRID 33
2.10 MARKET TESTING TYPE COVERAGE GRID 34
2.11 VENDOR SHARE ANALYSIS 35
2.12 SECONDARY SOURCES 36
2.13 ASSUMPTIONS 36

3 EXECUTIVE SUMMARY 37

4 PREMIUM INSIGHTS 40

4.1 PESTEL ANALYSIS 41
4.2 PORTER'S FIVE FORCES 42
4.3 GROWTH STRATEGIES ADOPTED BY KEY MARKET PLAYERS 43

5 INDUSTRY INSIGHTS 44

5.1 CONCLUSION 45

6 REGULATIONS OF THE ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET 46

7 MARKET OVERVIEW 48

7.1 DRIVERS 50
- 7.1.1 GROWING OVARIAN CANCER AWARENESS 50
- 7.1.2 IMPROVED DIAGNOSTIC PROCESSES AND TECHNIQUES 50
- 7.1.3 INCREASE IN NUMBER OF NEW CASES EVERY YEAR 51
- 7.1.4 IMPROVED IMAGING TECHNIQUES 51
7.2 RESTRAINS 52
- 7.2.1 HIGH COST OF DIAGNOSIS 52
- 7.2.2 ADVERSE EFFECTS OF THE TREATMENT 52
7.3 OPPORTUNITIES 53
- 7.3.1 INCREASING HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 53
- 7.3.2 GOVERNMENT INITIATIVES TOWARDS CANCER DIAGNOSTICS 53
7.4 CHALLENGES 54
- 7.4.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF CANCER DIAGNOSTIC PRODUCTS 54
- 7.4.2 LACK OF SKILLED PROFESSIONALS 55

8 ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 56

8.1 OVERVIEW 57
8.2 INSTRUMENTS 60
8.3 KITS AND REAGENTS 61

9 ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE 62

9.1 OVERVIEW 63
9.2 BLOOD MARKERS TESTING 66
9.3 MEDICAL IMAGING TEST 67
9.4 BIOPSY TEST 68
9.5 GENETIC TESTING 69

10 ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 70

10.1 OVERVIEW 71
10.2 EPITHELIAL TUMOR 74
10.3 GERM CELL 74
10.4 STROMAL CELL TUMOR 75

11 ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER 76

11.1 OVERVIEW 77
11.2 CANCER DIAGNOSTIC CENTERS 80
11.3 HOSPITAL LABORATORIES 80
11.4 RESEARCH INSTITUTES 81
11.5 OTHERS 82

12 ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY 83

12.1 ASIA-PACIFIC 84
- 12.1.1 JAPAN 90
- 12.1.2 CHINA 91
- 12.1.3 SOUTH KOREA 92
- 12.1.4 INDIA 93
- 12.1.5 AUSTRALIA 94
- 12.1.6 SINGAPORE 95
- 12.1.7 THAILAND 96
- 12.1.8 MALAYSIA 97
- 12.1.9 INDONESIA 98
- 12.1.10 PHILIPPINES 99
- 12.1.11 REST OF ASIA-PACIFIC 100

13 ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE 101

13.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 101

14 SWOT ANALYSIS 102

15 COMPANY PROFILE 103

15.1 F. HOFFMANN-LA ROCHE LTD 103
- 15.1.1 COMPANY SNAPSHOT 103
- 15.1.2 REVENUE ANALYSIS 104
- 15.1.3 COMPANY SHARE ANALYSIS 104
- 15.1.4 PRODUCT PORTFOLIO 104
- 15.1.5 RECENT DEVELOPMENTS 105
15.2 TOSOH INDIA PVT. LTD. 106
- 15.2.1 COMPANY SNAPSHOT 106
- 15.2.2 COMPANY SHARE ANALYSIS 106
- 15.2.3 PRODUCT PORTFOLIO 107
- 15.2.4 RECENT DEVELOPMENT 107
15.3 LUMINEX CORPORATION (2022) 108
- 15.3.1 COMPANY SNAPSHOT 108
- 15.3.2 COMPANY SHARE ANALYSIS 108
- 15.3.3 PRODUCT PORTFOLIO 109
- 15.3.4 RECENT DEVELOPMENT 109
15.4 QUEST DIAGNOSTICS INCORPORATED (2022) 110
- 15.4.1 COMPANY SNAPSHOT 110
- 15.4.2 REVENUE ANALYSIS 110
- 15.4.3 COMPANY SHARE ANALYSIS 111
- 15.4.4 PRODUCT PORTFOLIO 111
- 15.4.5 RECENT DEVELOPMENTS 112
15.5 THERMO FISHER SCIENTIFIC INC 113
- 15.5.1 COMPANY SNAPSHOT 113
- 15.5.2 REVENUE ANALYSIS 113
- 15.5.3 COMPANY SHARE ANALYSIS 114
- 15.5.4 PRODUCT PORTFOLIO 114
- 15.5.5 RECENT DEVELOPMENT 114
15.6 ABBOTT 115
- 15.6.1 COMPANY SNAPSHOT 115
- 15.6.2 REVENUE ANALYSIS 116
- 15.6.3 PRODUCT PORTFOLIO 116
- 15.6.4 RECENT DEVELOPMENT 116
15.7 ABCAM PLC (2022) 117
- 15.7.1 COMPANY SNAPSHOT 117
- 15.7.2 REVENUE ANALYSIS 118
- 15.7.3 PRODUCT PORTFOLIO 118
- 15.7.4 1.7.4 RECENT DEVELOPMENT 118
15.8 BIOSUPPLY LTD 119
- 15.8.1 COMPANY SNAPSHOT 119
- 15.8.2 PRODUCT PORTFOLIO 119
- 15.8.3 RECENT DEVELOPMENT 119
15.9 BIO-RADBIO LABORATORIES 120
- 15.9.1 COMPANY SNAPSHOT 120
- 15.9.2 REVENUE ANALYSIS 121
- 15.9.3 PRODUCT PORTFOLIO 121
- 15.9.4 RECENT DEVELOPMENTS 122
15.10 BIOVISION INC. 123
- 15.10.1 COMPANY SNAPSHOT 123
- 15.10.2 PRODUCT PORTFOLIO 123
- 15.10.3 RECENT DEVELOPMENT 123
15.11 BIOGENIX INC. PVT. LTD. 124
- 15.11.1 COMPANY SNAPSHOT 124
- 15.11.2 PRODUCT PORTFOLIO 124
- 15.11.3 RECENT DEVELOPMENT 124
15.12 BOSTER BIOLOGICAL TECHNOLOGY 125
- 15.12.1 COMPANY SNAPSHOT 125
- 15.12.2 PRODUCT PORTFOLIO 125
- 15.12.3 RECENT DEVELOPMENT 125
15.13 FOUNDATION MEDICINE 126
- 15.13.1 COMPANY SNAPSHOT 126
- 15.13.2 PRODUCT PORTFOLIO 126
- 15.13.3 RECENT DEVELOPMENT 126
15.14 FUJIREBIO 127
- 15.14.1 COMPANY SNAPSHOT 127
- 15.14.2 PRODUCT PORTFOLIO 127
- 15.14.3 RECENT DEVELOPMENT 127
15.15 GENWAY BIOTECH 128
- 15.15.1 COMPANY SNAPSHOT 128
- 15.15.2 PRODUCT PORTFOLIO 128
- 15.15.3 RECENT DEVELOPMENT 128
15.16 INEX INNOVATIVE PRIVATE LIMITED 129
- 15.16.1 COMPANY SNAPSHOT 129
- 15.16.2 PRODUCT PORTFOLIO 129
- 15.16.3 RECENT DEVELOPMENT 129
15.17 LCM GENETIC SRL 130
- 15.17.1 COMPANY SNAPSHOT 130
- 15.17.2 PRODUCT PORTFOLIO 130
- 15.17.3 RECENT DEVELOPMENT 130
15.18 LIFESPAN BIOSCIENCES, INC 131
- 15.18.1 COMPANY SNAPSHOT 131
- 15.18.2 PRODUCT PORTFOLIO 131
- 15.18.3 RECENT DEVELOPMENTS 132
15.19 MP BIOMEDICALS 133
- 15.19.1 COMPANY SNAPSHOT 133
- 15.19.2 PRODUCT PORTFOLIO 133
- 15.19.3 RECENT DEVELOPMENT 133
15.20 MONOBIND INC. 134
- 15.20.1 COMPANY SNAPSHOT 134
- 15.20.2 PRODUCT PORTFOLIO 134
- 15.20.3 RECENT DEVELOPMENT 134
15.21 MYRIAD GENETICS, INC. 135
- 15.21.1 COMPANY SNAPSHOT 135
- 15.21.2 REVENUE ANALYSIS 135
- 15.21.3 PRODUCT PORTFOLIO 136
- 15.21.4 RECENT DEVELOPMENT 136
15.22 NGENEBIO 137
- 15.22.1 COMPANY SNAPSHOT 137
- 15.22.2 PRODUCT PORTFOLIO 137
- 15.22.3 RECENT DEVELOPMENTS 138
15.23 R&D SYSTEMS, INC. 139
- 15.23.1 COMPANY SNAPSHOT 139
- 15.23.2 PRODUCT PORTFOLIO 139
- 15.23.3 RECENT DEVELOPMENT 139
15.24 SIEMENS MEDICAL SOLUTIONS 140
- 15.24.1 COMPANY SNAPSHOT 140
- 15.24.2 REVENUE ANALYSIS 140
- 15.24.3 PRODUCT PORTFOLIO 141
- 15.24.4 RECENT DEVELOPMENT 141

16 QUESTIONNAIRE 142

17 RELATED REPORTS 145

LIST OF TABLES

TABLE 1 24-MONTH EPISODE-OF-CARE COSTS FOR EARLY-STAGE AND LATE-STAGE CANCERS BY PAYER (USD BILLION) 47
TABLE 2 ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 54
TABLE 3 ASIA PACIFIC INSTRUMENTS IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 55
TABLE 4 ASIA PACIFIC KITS AND REAGENTS IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 56
TABLE 5 ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 60
TABLE 6 ASIA PACIFIC BLOOD MARKERS TESTING IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 61
TABLE 7 ASIA PACIFIC MEDICAL IMAGING TEST IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 62
TABLE 8 ASIA PACIFIC BIOPSY TEST IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 63
TABLE 9 ASIA PACIFIC GENETIC TESTING IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 64
TABLE 10 ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 68
TABLE 11 ASIA PACIFIC EPITHELIAL TUMOR IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 69
TABLE 12 ASIA PACIFIC GERM CELL IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 70
TABLE 13 ASIA PACIFIC STROMAL CELL TUMOR IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 70
TABLE 14 ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 74
TABLE 15 ASIA PACIFIC CANCER DIAGNOSTIC CENTERS IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 75
TABLE 16 ASIA PACIFIC HOSPITAL LABORATORIES IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 76
TABLE 17 ASIA PACIFIC RESEARCH INSTITUTES IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 76
TABLE 18 ASIA PACIFIC OTHERS IN OVARIAN CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 77
TABLE 19 ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 83
TABLE 20 ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 83
TABLE 21 ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 83
TABLE 22 ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 84
TABLE 23 ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 84
TABLE 24 JAPAN OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 85
TABLE 25 JAPAN OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 85
TABLE 26 JAPAN OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 85
TABLE 27 JAPAN OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 85
TABLE 28 CHINA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 86
TABLE 29 CHINA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 86
TABLE 30 CHINA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 86
TABLE 31 CHINA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 86
TABLE 32 SOUTH KOREA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 87
TABLE 33 SOUTH KOREA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 87
TABLE 34 SOUTH KOREA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 87
TABLE 35 SOUTH KOREA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 87
TABLE 36 INDIA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 88
TABLE 37 INDIA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 88
TABLE 38 INDIA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 88
TABLE 39 INDIA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 88
TABLE 40 AUSTRALIA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 89
TABLE 41 AUSTRALIA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 89
TABLE 42 AUSTRALIA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 89
TABLE 43 AUSTRALIA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 89
TABLE 44 SINGAPORE OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 90
TABLE 45 SINGAPORE OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 90
TABLE 46 SINGAPORE OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 90
TABLE 47 SINGAPORE OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 90
TABLE 48 THAILAND OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 91
TABLE 49 THAILAND OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 91
TABLE 50 THAILAND OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 91
TABLE 51 THAILAND OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 91
TABLE 52 MALAYSIA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 92
TABLE 53 MALAYSIA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 92
TABLE 54 MALAYSIA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 92
TABLE 55 MALAYSIA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 92
TABLE 56 INDONESIA OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 93
TABLE 57 INDONESIA OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 93
TABLE 58 INDONESIA OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 93
TABLE 59 INDONESIA OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 93
TABLE 60 PHILIPPINES OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 94
TABLE 61 PHILIPPINES OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 94
TABLE 62 PHILIPPINES OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 94
TABLE 63 PHILIPPINES OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 94
TABLE 64 REST OF ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 95
TABLE 65 REST OF ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET, BY PROCEDURE TYPE, 2021-2030 (USD MILLION) 95
TABLE 66 REST OF ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 95
TABLE 67 REST OF ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 95

LIST OF FIGURES

FIGURE 1 ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET : SEGMENTATION 19
FIGURE 2 ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET : DATA TRIANGULATION 22
FIGURE 3 ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET : DROC ANALYSIS 23
FIGURE 4 ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET : ASIA PACIFIC VS REGIONAL MARKET ANALYSIS 24
FIGURE 5 ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET : COMPANY RESEARCH ANALYSIS 24
FIGURE 6 ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET : INTERVIEW DEMOGRAPHICS 26
FIGURE 7 ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET : DBMR MARKET POSITION GRID 27
FIGURE 8 ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET : MARKET TESTING TYPE COVERAGE GRID 28
FIGURE 9 ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET : VENDOR SHARE ANALYSIS 29
FIGURE 10 ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET : SEGMENTATION 33
FIGURE 11 THE INCREASE IN THE AWARENESS ABOUT OVARIAN CANCER IS EXPECTED TO DRIVE THE ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2022 TO 2030 34
FIGURE 12 PRODUCT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET IN 2022 & 2030 34
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGE OF THE ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET 43
FIGURE 14 ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022 51
FIGURE 15 ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION) 52
FIGURE 16 ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030) 52
FIGURE 17 ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE 53
FIGURE 18 ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET: BY PROCEDURE TYPE, 2022 57
FIGURE 19 ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET: BY PROCEDURE TYPE, 2023-2030 (USD MILLION) 58
FIGURE 20 ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET: BY PROCEDURE TYPE, CAGR (2023-2030) 58
FIGURE 21 ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET: BY PROCEDURE TYPE, LIFELINE CURVE 59
FIGURE 22 ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022 65
FIGURE 23 ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION) 66
FIGURE 24 ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030) 66
FIGURE 25 ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE 67
FIGURE 26 ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET: BY END USER, 2022 71
FIGURE 27 ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION) 72
FIGURE 28 ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030) 72
FIGURE 29 ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE 73
FIGURE 30 ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 79
FIGURE 31 ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 80
FIGURE 32 ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 80
FIGURE 33 ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 81
FIGURE 34 ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023-2030) 81
FIGURE 35 ASIA PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 95